BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17109519)

  • 21. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.
    Hu J; Zhao G; Wang HX; Tang L; Xu YC; Ma Y; Zhang FC
    J Hematol Oncol; 2011 Mar; 4():11. PubMed ID: 21439076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials.
    Li W; Wang H; Li X
    Curr Med Res Opin; 2013 Nov; 29(11):1443-52. PubMed ID: 23927481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
    Ouyang G; Wu Y; Liu Z; Lu W; Li S; Hao S; Pan G
    Medicine (Baltimore); 2021 Dec; 100(48):e27870. PubMed ID: 35049189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer.
    Huang D; Fang J; Luo G
    J Cancer Res Ther; 2016 Oct; 12(Supplement):104-108. PubMed ID: 27721265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
    Zhang XW; Ma YX; Sun Y; Cao YB; Li Q; Xu CA
    Target Oncol; 2017 Jun; 12(3):309-321. PubMed ID: 28353074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
    Ciliberto D; Botta C; Correale P; Rossi M; Caraglia M; Tassone P; Tagliaferri P
    Eur J Cancer; 2013 Feb; 49(3):593-603. PubMed ID: 22989511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis.
    Zhu CP; Shi J; Chen YX; Xie WF; Lin Y
    Radiother Oncol; 2011 May; 99(2):108-13. PubMed ID: 21571383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.
    Chen L; Zhang M; Luo S
    Tumour Biol; 2014 Nov; 35(11):11551-8. PubMed ID: 25129442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
    O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
    Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
    Tu C; Zheng F; Wang JY; Li YY; Qian KQ
    Asian Pac J Cancer Prev; 2015; 16(14):5681-6. PubMed ID: 26320435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
    Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
    Vaccaro V; Bria E; Sperduti I; Gelibter A; Moscetti L; Mansueto G; Ruggeri EM; Gamucci T; Cognetti F; Milella M
    World J Gastroenterol; 2013 Jul; 19(28):4511-9. PubMed ID: 23901226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
    Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
    Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy and radiotherapy for advanced pancreatic cancer.
    Chin V; Nagrial A; Sjoquist K; O'Connor CA; Chantrill L; Biankin AV; Scholten RJ; Yip D
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011044. PubMed ID: 29557103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
    J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer.
    Dehua Z; Mingming C; Jisheng W
    PLoS One; 2018; 13(3):e0193814. PubMed ID: 29561887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.
    Gresham GK; Wells GA; Gill S; Cameron C; Jonker DJ
    BMC Cancer; 2014 Jun; 14():471. PubMed ID: 24972449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
    Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
    Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
    J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.